Drugs / AB-3028
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07285694 | Jan 2026 → May 2029 expected | prostate carcinoma | Arsenal Biosciences, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AB-3028 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07285694 ↗ |
| Action | Deplete | “These logic-gated T cells may help the body's immune system identify and kill cancer cells while sparing normal healthy tissues from toxicity.” NCT07285694 ↗ |
| Modality | Cell therapy | “autologous T cell therapy” NCT07285694 ↗ |
| Route | Intravenous | “single intravenous infusion” NCT07285694 ↗ |